Standard BioTools Inc.
LAB
Positions held
Your positionsLAB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $263.15M | Enterprise value | -$185.49M | Trailing P/E | — | Forward P/E | -67.03 |
| PEG | — | Price / book | 0.49 | Beta | 1.35 | Dividend yield | 0.00% |
| Revenue growth | -7.6% | Earnings growth | — | Gross margin | 50.5% | Operating margin | -38.9% |
| Profit margin | 100.4% | ROE | -11.2% | ROA | -6.6% | Debt / equity | 0.05 |
| Current ratio | 9.10 | Free cash flow | $176.58M | Analyst recommendation | none | Mean target | $1.35 |
| 52w high | $1.72 | 52w low | $0.63 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $20.1M | $21.1M | $23.8M | $19.6M | $21.8M | — |
| Op margin | -38.9% | -44.5% | -92.1% | -120.0% | -108.9% | — |
| Net income | -$26.8M | $127M | $19.3M | -$34.7M | -$33.5M | — |
| Gross margin | 52.4% | 53.5% | 47.8% | 48.5% | 48.8% | — |
| Gross profit | $10.5M | $11.3M | $11.4M | $9.5M | $10.6M | — |
| Operating income | -$7.8M | -$9.4M | -$21.9M | -$23.5M | -$23.7M | — |
- Revenue -5% vs prior quarter ($20M vs $21M).
- Gross margin 52.4% (was 53.5% prior quarter).
- Operating margin expanded to -39%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $85.3M | $91.0M | $106M | $97.9M | — |
| Op margin | -109.3% | -95.6% | -59.3% | -104.8% | — |
| Net income | -$74.9M | -$139M | -$74.7M | -$190M | — |
| Gross margin | 49.9% | 49.3% | 47.4% | 37.8% | — |
| Gross profit | $42.5M | $44.9M | $50.5M | $37.1M | — |
| Operating income | -$93.3M | -$87.0M | -$63.0M | -$103M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
2026-09-30 · Standard BioTools Provides Update on Sale of Mass Cytometry Business
2026-08-05 · Standard BioTools: Q2 Earnings Snapshot
2026-08-05 · Standard BioTools Reports Second Quarter 2026 Financial Results
2026-07-28 · Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
2026-07-22 · Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
2026-07-20 · Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Price (daily)
Full chart · RSI · MACD · patterns